Physician
Arizona Arthritis & Rheumatology Associates P C
Arizona Arthritis & Rheumatology Associates P C was paid $11.16M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C
PHOENIX, AZ 85032
PHOENIX, AZ 85032
33aNPI1366489254assigned 06/01/2006
33bProvider typeOrthopaedic Surgery Physician
28Total paid$11.16M
24GClaims156,501
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Orthopaedic Surgery Physician providers in Arizona
Rank by total paid#1 of 45
Median peer was paid$53K
This provider vs. median210×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,446 | $437K | |
| 2019 | 12,045 | $636K | |
| 2020 | 15,595 | $848K | |
| 2021 | 25,243 | $1.54M | |
| 2022 | 31,983 | $2.13M | |
| 2023 | 34,322 | $3.15M | |
| 2024incomplete | 29,867 | $2.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 65,460 | 61,895 | $3.79M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 15% | 20,347 | 17,587 | $1.72M |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 7.8% | 582 | 498 | $865K |
| 99205 | Prolong outpt/office vis | 7.0% | 6,590 | 6,385 | $779K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.8% | 7,211 | 7,024 | $647K |
| J0490 | Injection, belimumab, 10 mg | 5.6% | 281 | 245 | $628K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.5% | 7,253 | 6,845 | $618K |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 4.8% | 330 | 289 | $531K |
| J3262 | Injection, tocilizumab, 1 mg | 4.4% | 434 | 309 | $490K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.1% | 191 | 160 | $234K |
| 99443 | 1.7% | 3,068 | 2,928 | $194K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1.1% | 57 | 50 | $121K |
28 more codes
| 96415 | 1.0% | 4,027 | $112K | |
| 99442 | <1% | 2,744 | $102K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,642 | $80K |
| J0897 | Injection, denosumab, 1 mg | <1% | 180 | $78K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,534 | $47K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 48 | $41K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 12 | $22K |
| 76881 | <1% | 541 | $17K | |
| 20611 | <1% | 186 | $12K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,354 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 400 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 630 | $4K |
| 20610 | <1% | 53 | $3K | |
| 81002 | <1% | 701 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $1K |
| 99441 | <1% | 120 | $1K | |
| 20600 | <1% | 50 | $677.98 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 65 | $376.87 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 161 | $306.46 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 39 | $195.13 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 54 | $114.65 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 16 | $105.70 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 26 | $41.81 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 33 | $20.83 |
| 80053 | Comprehensive metabolic panel | 0% | 14 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 13 | $0.00 |
| 85652 | 0% | 13 | $0.00 | |
| 86140 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETERS, ERIC (MD)
| Provider | Location | Paid |
|---|---|---|
| Lagniappe Pharmacy 6, LLC | Opelousas, LA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.